HORSHAM, Pa., July 28, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its second quarter 2023 financial results on Wednesday, August 9, 2023. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 PM ET on the same day.
Wednesday, August 9, 2023, 4:30 PM ET
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13739272
Webcast: STRATA Skin Sciences Earnings Webcast
After the live webcast, the event will be archived for future reference on the STRATA Skin Sciences website at www.strataskinsciences.com under the investor relations section.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.72 |
Daily Change: | -0.17 -5.88 |
Daily Volume: | 1,869 |
Market Cap: | US$11.340M |
November 13, 2024 September 17, 2024 September 03, 2024 August 14, 2024 July 23, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load